NV
Therapeutic Areas
Dawah Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Oral Antibiotic | Bacterial infections | ANDA Filed/Pre-approval |
| GLP-1/GIP (Inferred) | Type 2 diabetes, weight management | Development |
| Cardiac Agent 1 | Acute heart failure, cardiac stress testing | Development |
| Diuretic | Edema, congestive heart failure, hypertension | Development |
| Injectable NSAID 1 | Short-term pain relief | Development |
| Ursodeoxycholic Acid | Gallstone dissolution, primary biliary cholangitis | Development |
| Anti-platelet | Cardiovascular diseases | Development |
| Sedative | Sedation in intensive care and surgical settings | Development |